Effectiveness of 0.05% cyclosporine A eye drops for dry eye disease in patients with thyroid-associated ophthalmopathy: a prospective, parallel-group cohort study.
- 1Department of Ophthalmology, General Hospital of Northern Theater Command, Shenyang, China.
Abstract
Background
Thyroid-associated ophthalmopathy (TAO) is frequently accompanied by dry eye disease (DED), which can lead to ocular surface damage and decreased visual quality. This study aimed to evaluate the effectiveness of 0.05% cyclosporine A (CsA) eye drops in the treatment of TAO-related DED.Methods
This prospective, parallel-group cohort study included 86 participants diagnosed with TAO-related DED. Participants were divided into either the CsA group (n = 43) or the control group (n = 43). The CsA group received 0.05% CsA eye drops (twice daily), and control group received polyethylene glycol eye drops (four times daily). Ocular parameters were assessed pre-treatment and at 1, 2, and 3 months post-treatment.Results
After 3 months of treatment, the CsA group demonstrated significantly better outcomes than the control group in ocular surface disease index (OSDI) scores, fluorescein tear breakup time (FBUT), and Schirmer I test (SIT) values (all P < 0.05), with between-group differences emerging as early as month 1. Corneal fluorescein staining (CFS) scores also showed significantly greater improvement in the CsA group (P < 0.05). Both groups exhibited comparable improvements in tear meniscus height (TMH) and ocular redness scores over time (P > 0.05). The incidence of adverse events was low in both groups, with all events being mild.Conclusion
0.05% CsA eye drops were associated with improvement in tear film stability, tear secretion, and corneal epithelial integrity in participants with TAO-related DED, and were well tolerated over the 3-month follow-up period.
Related
- Comparative study on the clinical effectiveness of low-concentration cyclosporine eye drops in patients with dry eye disease
- Real-world effectiveness and safety of enavogliflozin in patients with type 2 diabetes: A 24-week prospective multicenter observational study in Korea.
- Effectiveness and safety of imeglimin in routine clinical practice among Indian patients with type 2 diabetes mellitus: a prospective, non-interventional, real-world observational study (INDI-TIMES 2.0)
- Effectiveness of metformin as initial treatment on the metabolic profile of Saudi patients newly diagnosed with type 2 diabetes mellitus : A prospective observational study
- Real-World Effectiveness of Budesonide/Glycopyrronium/Formoterol (BGF) Fixed-Dose Combination in Patients with COPD (RECORD Study): A Prospective Observational Study
BibTeX
@article{zhang2026effectiveness,
title = {{Effectiveness of 0.05% cyclosporine A eye drops for dry eye disease in patients with thyroid-associated ophthalmopathy: a prospective, parallel-group cohort study.}},
author = {Yu Zhang and Juan Bao and Cuiyu Wang and Ruiyao Gao and Kai Zhang and Yingxin Chen},
journal = {Frontiers in medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1951598},
url = {https://europepmc.org/article/MED/42908839},
note = {CC BY},
}
RIS
TY - JOUR
TI - Effectiveness of 0.05% cyclosporine A eye drops for dry eye disease in patients with thyroid-associated ophthalmopathy: a prospective, parallel-group cohort study.
AU - Yu Zhang
AU - Juan Bao
AU - Cuiyu Wang
AU - Ruiyao Gao
AU - Kai Zhang
AU - Yingxin Chen
PY - 2026
DA - 2026/10/07
JO - Frontiers in medicine
DO - 10.3389/fmed.2026.1951598
UR - https://europepmc.org/article/MED/42908839
AB - Background Thyroid-associated ophthalmopathy (TAO) is frequently accompanied by dry eye disease (DED), which can lead to ocular surface damage and decreased visual quality. This study aimed to evaluate the effectiveness of 0.05% cyclosporine A (CsA) eye drops in the treatment of TAO-related DED.Methods This prospective, parallel-group cohort study included 86 participants diagnosed with TAO-related DED. Participants were divided into either the CsA group (n = 43) or the control group (n = 43). The CsA group received 0.05% CsA eye drops (twice daily), and control group received polyethylene glycol eye drops (four times daily). Ocular parameters were assessed pre-treatment and at 1, 2, and 3 months post-treatment.Results After 3 months of treatment, the CsA group demonstrated significantly better outcomes than the control group in ocular surface disease index (OSDI) scores, fluorescein tear breakup time (FBUT), and Schirmer I test (SIT) values (all P < 0.05), with between-group differences emerging as early as month 1. Corneal fluorescein staining (CFS) scores also showed significantly greater improvement in the CsA group (P < 0.05). Both groups exhibited comparable improvements in tear meniscus height (TMH) and ocular redness scores over time (P > 0.05). The incidence of adverse events was low in both groups, with all events being mild.Conclusion 0.05% CsA eye drops were associated with improvement in tear film stability, tear secretion, and corneal epithelial integrity in participants with TAO-related DED, and were well tolerated over the 3-month follow-up period.
SN - 2296-858X
ER -